Loading
AT
Akero Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 27 Mar 2025.
Akero Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Akero Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, the company's managers filed 34 filings, from 14 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Insider buying of Akero Therapeutics, Inc. has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
Compared with its exchange (5,810 companies, median 19 filings), a count of 34 filings is above the norm. Over the whole record (from 2021), the tally stands at 11 purchases and 123 sales.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
326
Thresholds
n/a
Buy Volume
€43M
11 ops. · all time
Sell Volume
€97M
123 ops. · all time
Who traded when
BuySaleAndrew Cheng19 sales
Jonathan Young12 sales
Catriona Yale7 sales
Timothy Rolph5 sales
William Richard White5 sales
Patrick Lamy4 sales
+3 other insiders
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-US$217M
Last declaration on 9 December 2025
Declarations326 total
5,088 sharesCommon StockSEC:0001193125-25-312111:0
9,398 sharesCommon StockSEC:0001193125-25-312115:0
277,075 sharesCommon StockSEC:0001193125-25-312131:0
10,179 sharesCommon StockSEC:0001193125-25-312109:0
9,398 sharesCommon StockSEC:0001193125-25-312098:0
93,000 sharesCommon StockSEC:0001193125-25-312122:0
3,059 sharesCommon StockSEC:0001193125-25-312099:0
238,339 sharesCommon StockSEC:0001193125-25-312116:0
136,301 sharesCommon StockSEC:0001193125-25-312127:0
9,398 sharesCommon StockSEC:0001193125-25-312134:0
27,227 sharesCommon StockSEC:0001193125-25-312100:0
152,616 sharesCommon StockSEC:0001193125-25-312092:0
20,000 sharesCommon StockSEC:0001193125-25-312092:1
20,000 sharesCommon StockSEC:0001193125-25-312092:2
20,000 sharesCommon StockSEC:0001193125-25-312092:3
47,573 sharesCommon StockSEC:0001193125-25-312092:4
26,832 sharesCommon StockSEC:0001193125-25-312099:1
47,573 sharesCommon StockSEC:0001193125-25-312100:1
47,573 sharesCommon StockSEC:0001193125-25-312109:1
21,263 sharesCommon StockSEC:0001193125-25-312111:1
43,810 sharesCommon StockSEC:0001193125-25-312116:1
1,200,000 sharesCommon StockSEC:0001193125-25-312122:1
9,398 sharesCommon StockSEC:0001193125-25-312122:2
25 of 326 declarations
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc. (ticker: AKRO) is a United States-based biotechnology company listed on the Nasdaq market in the United States. It is a clinical-stage specialty biotech focused on severe metabolic liver disease, with its investment case anchored on the development of therapies for MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH. For international investors, Akero should be viewed primarily as a science- and execution-driven story rather than a diversified commercial pharma platform: the company’s equity value is largely tied to the success of its lead clinical program and to its ability to translate clinical data into regulatory and ultimately commercial value. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1744659/000095017025029514/akro-20241231.htm?utm_source=openai))
Akero was founded in 2018 with backing from Apple Tree Partners, and early financing supported the development of its first lead candidate. The company established its headquarters in San Francisco and later South San Francisco, California, placing it in the core US biotech ecosystem. This matters strategically: Akero is built like a typical West Coast clinical biotech, with a lean operating model, a high R&D intensity, and a capital structure designed to fund multi-year clinical development before any commercial launch. ([ir.akerotx.com](https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-closes-65-million-series-financing-advance/?utm_source=openai))
Read moreShow less
The company’s core asset is efruxifermin, or EFX, an FGF21 analog. According to SEC filings, EFX is Akero’s lead product candidate and the basis of its clinical platform. The drug is being developed as a potential treatment for patients with MASH, including both pre-cirrhotic and compensated cirrhotic disease. That concentration on a single program creates a classic biotech risk/reward profile: if the clinical data continue to support a meaningful efficacy and safety profile, Akero could emerge as a leading metabolic disease specialist; if results disappoint, the downside can be material because the pipeline is relatively concentrated. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1744659/000095017025029514/akro-20241231.htm?utm_source=openai))
From a competitive standpoint, Akero operates in a crowded and strategically important segment of liver and metabolic medicine, where multiple companies are pursuing market share in MASH. Akero’s differentiation lies in its FGF21-based mechanism and the depth of its clinical development around EFX. The company does not yet have a commercial product, so its valuation depends heavily on trial readouts, safety observations, regulatory momentum, and management credibility with institutional investors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1744659/000095017025029514/akro-20241231.htm?utm_source=openai))
Geographically, Akero remains largely US-centered in operations, with headquarters in California and R&D activity concentrated in the United States, even though the disease burden it targets is global. Recent company communications in 2025 indicate continued advancement of multiple clinical trials for EFX, while SEC Form 4 filings show ongoing insider-transaction activity that investors may monitor for governance and sentiment signals. In short, Akero is a Nasdaq-listed United States biotech story built around a single lead asset, a high-unmet-need indication, and a catalyst-heavy clinical timeline. ([akerotx.com](https://akerotx.com/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
